Roche Launches Best-selling Drug in China

World leading pharmaceutical manufacturer Roche has launched one of its best-selling drugs on the Chinese market.

The State Drug Administration recently endorsed the entry of Dilatrend, Roche's name brand drug used to treat heart failure, into Chinese hospitals.

Together with the Chinese Medical Association's Cardio-Vascular Society, Roche plans to carry out a large-scale publicity drive in 12 major cities throughout the country, helping cardiologists improve their diagnosis ability and upgrade people's awareness of disease prevention.

Meanwhile, Roche will organize clinical research to observe the safety and effectiveness of Dilatrend, medicinally termed carvedilol, among Chinese patients.

Wu Ning, chairwoman of the Cardio-Vascular Society, said that early diagnosis is extremely important in patients suffering from chronic heart failure.

Statistics from the World Health Organization show that the global incidence of heart failure is nearly two percent. About 37 percent of patients die two years after diagnosis, and 82 percent of them die six years after diagnosis.

Experts estimate that China has 3.6 million people suffering from heart failure.






People's Daily Online --- http://english.peopledaily.com.cn/